Sino Biopharmaceutical Submits NDA for Anlotinib and Penpulimab Combo in HCC to NMPA
China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced the submission of a New Drug Application...
Sihuan Pharmaceutical’s Huisheng Pharm Strikes Exclusive Deal for Semaglutide Biosimilar in China
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced an exclusive licensing agreement between...
Innovent Biologics’ IBI354 Earns Breakthrough Therapy Designation for Ovarian Cancer Treatment
The Center for Drug Evaluation (CDE) website has indicated that China-based Innovent Biologics, Inc. (HKG:...
CDE Includes Double-Crane’s Hydroxocobalamine and Sanofi Genzyme’s Fitusiran in Rare Disease Care Plan
China’s Center for Drug Evaluation (CDE) has announced the inclusion of China Resources Double-Crane Pharmaceutical...
Apeiron Therapeutics Initiates Phase Ia/B Study for GTA182 in Solid Tumors with MTAP Deficiency
Apeiron Therapeutics, a biomarker-driven cancer therapy developer with operations in Shanghai, China, and San Francisco,...
BI Partners with Sinopharm for Promotion of Sifrol and Pradaxa in China
German pharmaceutical major Boehringer Ingelheim (BI) has entered into a partnership with China-based Sinopharm Group...
Medtronic Receives US Approval for InPen App with Missed Meal Dose Detection
US-Irish firm Medtronic (NYSE: MDT) has announced US market approval for its new InPen app,...
CStone Pharmaceuticals Partners with Pharmalink for Suemalimab Commercialization in MENA and South Africa
China-based CStone Pharmaceuticals (HKG: 2616) has announced a strategic commercial collaboration with Pharmalink Store –...
NMPA Approves Alpha Biopharma’s Zorifertinib for First-Line NSCLC Treatment with CNS Metastases
The National Medical Products Administration (NMPA) has granted approval to China-based Alpha Biopharma’s zorifertinib, commercially...
Pfizer’s Hympavzi Receives European Commission Approval for Hemophilia A and B
US pharmaceutical major Pfizer Inc. (NYSE: PFE) has announced that the European Commission (EC) has...
Guangdong Zhongsheng Pharmaceutical’s RAY1225 Shows Positive Results in Phase II Study
Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317), a China-based pharmaceutical company, has announced positive top-line...
Shenzhen Chipscreen Biosciences Announces Private Placement to Fund Drug R&D and Expansion
China-based biopharmaceutical company Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321) has announced plans for a...
US FDA Grants ODD to Ractigen’s siRNA Therapy RAG-21 for ALS Treatment
China-based small activating RNA (saRNA) drug developer, Ractigen Therapeutics, has announced that it has received...
UCB’s Bimzelx Receives US FDA Approval for Moderate to Severe Hidradenitis Suppurativa
Belgium-based biopharmaceutical company UCB (FRA: UNC) has announced that the US Food and Drug Administration...
Alloy Therapeutics Partners with Takeda on iPSC-Derived CAR-T and CAR-NK Therapies
US-based Alloy Therapeutics Inc. has announced a strategic partnership with Japan-headquartered Takeda Pharmaceutical Co., Ltd...
BeiGene Reaches Patent Settlement with MSN Pharmaceuticals for Brukinsa
China-based BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235), which is in the process of...
Laekna and Eli Lilly & Co. Enter Clinical Cooperation to Advance Obesity Treatment LAE102
Sino-US biotech company Laekna, Inc. (HKG: 2105) has announced a significant clinical cooperation agreement with...
GSK’s Linerixibat Demonstrates Efficacy in Phase III GLISTEN Study for Cholestatic Pruritus
UK-based pharmaceutical giant GlaxoSmithKline (GSK; NYSE: GSK) has announced positive headline results from the Phase...
Astellas Pharma’s Izervay sNDA for Geographic Atrophy Receives FDA Complete Response Letter
Japan-based Astellas Pharma Inc. (TYO: 4568) has announced that its supplemental New Drug Application (sNDA)...
Bayer AG Secures Exclusive Rights to Cytokinetics’ Aficamten in Japan
Germany-based Bayer AG (ETR: BAYN) has announced a significant collaboration and license agreement with US-based...